Medically reviewed by Edward Tavel, MD, Medical Director · Last reviewed 10 September 2026
“Can a blood test detect cancer in the body?” is one of the most common questions people bring to us, and the honest answer depends entirely on which blood test you mean.
There are really only two ways to look for cancer. You can look for a signal — some trace in the blood that suggests cancer cells are present somewhere. Or you can look at anatomy — actual images of your internal structures, examined for anything that looks wrong. Almost every test you will encounter falls into one of those two categories, and understanding which one you are dealing with clears up most of the confusion.
What a routine CBC can and cannot tell you
Let us start here, because a great many people arrive at this question after a routine blood panel came back with something flagged.
A complete blood count, or CBC, is not a cancer screening test. It was never designed to be one. It measures the cells circulating in your blood: red cells, white cells and platelets. It tells your doctor about anemia, infection, clotting and general blood health.
A CBC can sometimes point toward cancer, and it is worth being clear about how. Abnormal white cell counts or unexplained anemia occasionally prompt further investigation, and cancers of the blood and bone marrow — leukemia in particular — can show up as unusual patterns in these numbers. That is a genuine and useful function.
But two things follow from this, and they cut in both directions. First, an abnormal CBC usually has a non-cancer explanation. Infection, iron deficiency, inflammation, recent illness, medication and even dehydration can all move these numbers. An out-of-range result is a reason for your doctor to look further, not a reason to assume the worst. Second, a normal CBC does not rule cancer out. Most solid tumors — in the lung, kidney, pancreas, ovary or elsewhere — can be present without producing any change in a complete blood count at all.
If a CBC result is worrying you, the most useful next step is asking the physician who ordered it what specifically caught their attention. That conversation resolves the great majority of these questions.
Tumor markers and their limits
The other blood tests people ask about are tumor markers: CA-125, PSA, CEA and others. These measure substances that certain cancers produce.
Their main role is monitoring rather than screening. If someone has a known cancer, tracking a marker over time can show whether treatment is working or whether disease has returned. Some markers also have a place in specific diagnostic situations, where a doctor already has a reason to suspect a particular condition.
What they are generally not suited to is screening the general population. The trouble is specificity. These substances rise in plenty of benign conditions — CA-125, for instance, can be elevated by endometriosis, fibroids, pregnancy and even menstruation — and they can stay normal in people who do have cancer. Used broadly in healthy people, they generate far more confusion than clarity. PSA is a partial exception with its own established guidelines, which is a conversation to have with your physician rather than a test to order on your own.
How multi-cancer blood tests differ
Multi-cancer early detection tests, or MCED tests, work on a different principle from either of the above. Instead of counting cells or measuring a single protein, they look for circulating tumor DNA and other biomarkers that tumors shed into the bloodstream. A single draw is analyzed for that material, and if enough is present, the test reports that a cancer signal was detected. Some also predict where in the body the signal is likely coming from.
This is a genuine advance, and it extends toward cancers that have no routine screening test at all. But it comes with defined boundaries. Cancerguard’s own labeling states it is not indicated for breast cancer, prostate cancer or pre-cancerous lesion screening. Those first two are the most frequently diagnosed cancers in the United States — the American Cancer Society projects 321,910 new breast cancer cases and 333,830 new prostate cancer cases in 2026, out of roughly 2,114,850 total diagnoses, or about 31% of all new cancers. Galleri is positioned explicitly as an addition to standard screening, not a substitute for it. Neither test is FDA-approved, and no MCED test has been shown to reduce cancer deaths. Our overview of the Cancerguard test goes through the details.
What imaging sees
Imaging asks the other question entirely: what is physically there?
MRI produces detailed pictures of soft tissue using a magnetic field and radio waves, with no ionizing radiation and, in our protocols, no contrast dye. A sequence called diffusion-weighted imaging is particularly useful for this purpose. It measures how water moves through tissue, and because tumor tissue is typically more densely packed than healthy tissue, abnormalities tend to stand out against their surroundings.
The important difference is that imaging does not depend on a tumor releasing anything. It also produces information a blood test structurally cannot: where something is, how large it is, what shape it has and how it relates to nearby structures. Our board-certified radiologists read those images and describe what they find.
Why size matters for both approaches
Both approaches share a floor, and it is worth naming.
For a blood test, the amount of tumor material circulating scales with how much tumor is present. A very small, very early tumor may simply not shed enough DNA to cross the detection threshold. Sensitivity at stage I has been reported in the low tens of percent across MCED validation studies — meaning the great majority of the earliest cancers are missed. The biology creates a limit precisely where early detection would help most.
For imaging, the constraint is resolution. Something has to be large enough to appear on an image before radiologists can see it. That threshold is small, but it is not zero.
Neither approach can find what is too small to register. That is not a failure of either technology; it is the current state of the science, and it is why screening is repeated over time rather than done once.
What neither can do
Neither a blood test nor a scan can promise you do not have cancer. A negative result of any kind means nothing was detected, which is not the same as nothing being there.
Neither replaces the screening with the strongest evidence behind it: mammography, colonoscopy, cervical screening, PSA discussion with your doctor, and low-dose CT if you have a smoking history. And there are areas each simply does not cover. Whole-body MRI is poor at detecting small lung nodules, with published sensitivity around 23% for indeterminate pulmonary nodules — low-dose CT remains the only lung screening with demonstrated mortality benefit. MRI does not evaluate the lining of the colon and does not characterize thyroid nodules, which are assessed by ultrasound. A whole-body protocol is not a dedicated breast or prostate MRI. Across published studies, confirmed cancer is found in roughly 1% to 2% of asymptomatic people scanned, with a pooled rate of 1.57%, and incidental findings have been reported in up to 97%.
Knowing which question a test is answering is what keeps a result in proportion. If you would like to think through how these approaches fit together, our comparison of cancer blood tests and whole-body MRI is a good place to continue, and our team is happy to talk it through whenever you are ready.
Frequently asked questions
Can a blood test detect cancer anywhere in the body?
Some can detect signals associated with many cancer types, but none covers every cancer and no blood test is accurate enough for a negative result to rule cancer out. Multi-cancer early detection tests look for tumor DNA shed into the blood; Cancerguard is not indicated for breast or prostate cancer screening, and neither available test is FDA-approved.
Does a CBC blood test indicate cancer?
A complete blood count is not a cancer screening test. It can show abnormalities such as anemia or unusual white cell counts that sometimes prompt further investigation, and it can be associated with blood cancers like leukemia. But an abnormal CBC usually has a non-cancer explanation, and a normal CBC does not rule cancer out.
What cancers do not show up in blood tests?
Most solid tumors can be present without changing a routine blood panel, and early-stage tumors often shed too little DNA for a multi-cancer test to detect — sensitivity at stage I has been reported in the low tens of percent across MCED validation studies. Breast and prostate cancers, the two most commonly diagnosed in the United States, fall outside Cancerguard’s stated indication.
What is the difference between a blood test and a scan for cancer?
A blood test looks for a chemical signal that a tumor has released. A scan looks at anatomy directly and can show location, size and shape. A blood test may raise a question; imaging is usually how that question gets answered. Neither replaces mammography, colonoscopy, PSA discussion or low-dose CT.
Sources
- Cancer statistics, 2026
- Cancerguard® Multi-Cancer Early Detection Test
- Frequently Asked Questions (FAQs) for Patients
- Frequently Asked Questions (FAQs) for Providers
- Safety Information
- Tumor Marker Tests in Common Use
- Questions and Answers about Multi-Cancer Detection Tests
- Multi-Cancer Early Detection Tests: State of the Art and Implications for Radiologists
- Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis
- Complete blood count (CBC)
A whole-body MRI at MRI Wellness looks at the brain, spine, chest, abdomen and pelvis in a single session, without radiation or contrast dye. No referral is needed.
